David A. Siegel Relay Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 614,200 shares of RLAY stock, worth $2.92 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

614,200

Previous 424,800 44.59%

Holding current value

$2.92 Million

Previous $2.77 Million 57.02%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $1.18 Million - $1.8 Million	189,400 Added 44.59%	614,200 $4.35 Million
Q2 2024 Aug 14, 2024	BUY	$5.9 - $8.02 $179,950 - $244,610	30,500 Added 7.74%	424,800 $2.77 Million
Q1 2024 May 15, 2024	BUY	$7.5 - $12.07 $485,250 - $780,929	64,700 Added 19.63%	394,300 $3.27 Million
Q4 2023 Feb 14, 2024	BUY	$6.01 - $11.48 $146,644 - $280,112	24,400 Added 7.99%	329,600 $3.63 Million
Q3 2023 Nov 14, 2023	BUY	$8.24 - $12.97 $2.4 Million - $3.77 Million	290,800 Added 2019.44%	305,200 $2.57 Million
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $25,974 - $47,502	2,600 Added 22.03%	14,400 $180,000
Q1 2023 May 15, 2023	SELL	$15.0 - $22.76 $447,000 - $678,248	-29,800 Reduced 71.63%	11,800 $194,000
Q4 2022 Feb 14, 2023	BUY	$14.16 - $24.02 $312,936 - $530,842	22,100 Added 113.33%	41,600 $621,000
Q3 2022 Nov 14, 2022	BUY	$18.07 - $31.37 $352,365 - $611,715	19,500 New	19,500 $436,000

Others Institutions Holding RLAY

# of Institutions

204

Shares Held

156M

Call Options Held

207K

Put Options Held

40K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $571M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account